title: Hyaluronic acid-supported combination of water insoluble immunostimulatory compounds for anti-cancer immunotherapy.
abstract: A novel powder-form combination adjuvant system containing two immunostimulatory compounds was firstly developed and evaluated as a therapeutic intervention for cancer immunotherapy. With the help of hyaluronic acid (HA), water insoluble monophosphoryl lipid A (MPL), QS21 and imiquimod (R837), could be easily dispersed in aqueous solution and lyophilized as powder-form, which have an advantage in room-temperature storage stability compared with those conventional liquid formulation that requires cold storage. Two kinds of HA-based combination vaccine adjuvants (HA/MPL/QS21, HMQ and HA/MPL/R837, HMR) contributed to the increase of both humoral and cellular immunity, which is very important for efficient cancer immunotherapy. Through the challenge experiments in EG7-OVA (mouse lymphoma-expressing OVA) tumor-bearing mice model, we found out that the immunostimulatory effects of HMQ and HMR were successful in the inhibition of tumor proliferation. Taken together, both HA-based powder-form combination adjuvant systems are expected to be used as potent prophylactic and therapeutic cancer vaccine.
authors.affiliation: School of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea.
authors.forename: Woo Jung
authors.initials: WJ
authors.lastname: Shin
authors.affiliation: Nanomedical Systems Laboratory, SKKU Advanced Institute of Nanotechnology (SAINT), Sungkyunkwan University, Suwon 16419, Republic of Korea.
authors.forename: Hyun Jong
authors.initials: HJ
authors.lastname: Noh
authors.affiliation: Nanomedical Systems Laboratory, SKKU Advanced Institute of Nanotechnology (SAINT), Sungkyunkwan University, Suwon 16419, Republic of Korea.
authors.forename: Young-Woock
authors.initials: YW
authors.lastname: Noh
authors.affiliation: Nanomedical Systems Laboratory, SKKU Advanced Institute of Nanotechnology (SAINT), Sungkyunkwan University, Suwon 16419, Republic of Korea.
authors.forename: Sohyun
authors.initials: S
authors.lastname: Kim
authors.affiliation: School of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea.
authors.forename: Soong Ho
authors.initials: SH
authors.lastname: Um
authors.affiliation: School of Chemical Engineering, Sungkyunkwan University, Suwon 16419, Republic of Korea; Nanomedical Systems Laboratory, SKKU Advanced Institute of Nanotechnology (SAINT), Sungkyunkwan University, Suwon 16419, Republic of Korea. Electronic address: yongtaik@skku.edu.
authors.forename: Yong Taik
authors.initials: YT
authors.lastname: Lim
mesh_terms: D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000627:therapeutic use*; D000634:Aminoquinolines / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D000818:Animals; D019496:Cancer Vaccines / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D004337:Drug Carriers; D005260:Female; D006820:Hyaluronic Acid / Q000737:chemistry / Q000494:pharmacology*; D006860:Hydrogen Bonding; D000077271:Imiquimod; D007167:Immunotherapy; D008050:Lipid A / Q000031:analogs & derivatives / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D008223:Lymphoma / Q000276:immunology / Q000628:therapy*; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D012503:Saponins / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D012995:Solubility
chemical_list: D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D019496:Cancer Vaccines; D004337:Drug Carriers; D008050:Lipid A; D012503:Saponins; C078785:saponin QA-21V1; D006820:Hyaluronic Acid; C048436:monophosphoryl lipid A; D000077271:Imiquimod
keywords: Cancer immunotherapy; Cellular immunity; Hyaluronic acid; Immunostimulation; Powder-form adjuvant